
CLAIMS


1. A compound of formula (I), or a pharmaceutically acceptable salt thereof,




(I)

wherein Z is a flavagline analog.

2. The compound of claim 1, which is selected from the group consisting of



, and



,

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound of any one of claims 1-2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. The use of an effective amount of a compound of any one of claims 1-2, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating cancer in a subject in need thereof.

5. The use of a compound of any one of claims 1-2, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for targeting a drug to a tumor or cancer cell in a subject.

6. The use of any one of claims 4-5, wherein the compound, or the pharmaceutically acceptable salt thereof, localizes or travels to the cytoplasm or organelle of the tumor or cancer cell.

7. The use of any one of claims 4-6, wherein the compound, or the pharmaceutically acceptable salt thereof, is selective for cancer cells in the subject.

8. The use of any one of claims 4-7, wherein the compound, or the pharmaceutically acceptable salt thereof, is incorporated into at least about 2-fold more tumor or cancer cells than healthy cells.

9. The use of any one of claims 4-8, wherein the cancer is melanoma, brain cancer, lung cancer, adrenal cancer, liver cancer, renal or kidney cancer, pancreatic cancer, esophageal cancer, gastric cancer, stomach cancer, colon cancer, colorectal cancer, anal cancer, prostate cancer, ovarian cancer, breast cancer, cervical cancer, lymphoma, leukemia, myeloma, hematologic cancer, hepatocarcinoma, retinoblastoma, glioma, sarcoma, blastoma, squamous cell carcinoma, adenocarcinoma, or a combination thereof.

10. The use of any one of claims 4-9, wherein the cancer is melanoma, lung cancer, colorectal cancer, breast cancer, or a combination thereof.

11. The use of any one of claims 4-10, wherein

the lung cancer comprises small cell lung cancer, non-small cell lung cancer, or a combination thereof;

the melanoma comprises superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, amelanotic melanoma, nevoid melanoma, spitzoid melanoma, desmoplastic melanoma, or a combination thereof;

the colorectal cancer comprises adenocarcinoma; or

the breast cancer comprises invasive breast ductal carcinoma, metastatic breast cancer, inflammatory breast cancer, triple negative breast cancer, ductal carcinoma in situ, or a combination thereof.

12. The use of any one of claims 4-11, wherein the cancer comprises cancer stem cells.

13. The use of any one of claims 4-12, wherein the cancer comprises metastatic cancer cells.

14. The use of any one of claims 4-13, wherein the cancer comprises circulating tumor cells.

15. The use of any one of claims 4-14, wherein the subject is human.